Aurgalys Team
Selected Customers
Home
Interim Management
Quantum Genomics [ALQGC]
Corporate Finance
Management Assistance
Due Diligence
Interim Management
Investor Assistance
Onxeo [ONXEO]
Diaxonhit [ALEHT]
 

Sep. 1st, 2015: Aurgalys initiates coverage on Abivax [Euronext: ABVX]

septembre 01, 2015

Paris- Evry, France, Sep. 1st, 2015 – Aurgalys, a global provider for life sciences and healthcare companies through corporate finance, business development and interim management services, initiates coverage on Abivax.

« Abivax is a biopharmaceutical company, specializing in the development of antiviral drugs and vaccines against infectious diseases. Its lead products include ABX203, for chronic hepatitis B management (currently in Phase II/III) and ABX464, for HIV patients (Phase IIa). Abivax has built strong partnerships with research institutions such as the CIGB in Cuba (ABX203), the Scripps Institute, French CNRS etc. Abivax also secured an agreement with the Finlay Institute in Cuba for marketing three prophylactic vaccines (typhoid fever, meningitis B/C and leptospirosis) in selected territories in Asia, Africa and South America. Our target price for Abivax as of August 31st, 2015, is €26.60/share. »

You can download the coverage initiation report at the following link:

Comments are closed.